AICF's 2020-21 Fellow:
Gabriele Casitati, MD
Increase safety and efficacy of cancer adoptive immunotherapy
"Acute myeloid leukemia (AML) is a life-threatening malignancy still in dire need of effective treatment options. During my hematology residency in Milan, I exploited cutting-edge single cell assays to unravel healthy bone marrow and acute myeloid leukemia stem cell heterogeneity. Now, as a post-doc in Dr. Genovese lab at Dana-Farber Cancer Institute, I aim to develop a novel gene-editing approach to enable adoptive anti-leukemia immunotherapies while sparing normal hematopoietic cells. If successful, this strategy will allow the targeted treatment of high-risk or relapsed AML patients and, at the same time, avoid life-threatening toxicities."